Company intelligence / Profile preview

DNAVEC

Tsukuba, Ibaraki Prefecture, Japaniavi.org ↗

Ownership: Private
Development stage: Other

Overview

DNAVEC was a pioneering Japanese biotechnology company specializing in the development of non-integrating viral vectors—specifically Sendai virus—for efficient gene delivery and generation of induced pluripotent stem cells (iPSCs). Its technologies have been widely adopted as research tools globally. The company partnered with major organizations such as Life Technologies and IAVI to advance applications ranging from stem cell generation to novel vaccine strategies. It was succeeded by ID Pharma Co., Ltd., which continues its core technological legacy.

Therapeutic areas: Infectious DiseasesOther
Modalities: DNA vaccineViral vectoriPSC technologyRNA therapy
Industry: Non-Drug Biotech

Partnerships

Life Technologies Corporation/Invitrogen/Thermo Fisher ScientificInternational AIDS Vaccine Initiative (IAVI)

Beyond the preview

Go deeper on DNAVEC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNAVEC.

Explore the full profile